![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 7
Zeitschriftenartikel
Prat, A.; Ortega, V.; Villagrasa, P.; Paré, L.; Galván, P.; Oliveira, M.; Nucíforo, P.; Lluch, A.; Morales, S.; Amillano, K.; Lopez, R.; Gonzalez, R.; Manso, L.; Martinez, J.; Llombart, A.; Peña, L. de la; Cosimo, S. di; Rubio, I. T.; Harbeck, N.; Baselga, J. und Cortés, J.
(2017):
Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer.
In: Cancer Research, Bd. 77
Shi, W.; Jiang, T.; Nuciforo, P.; Hatzis, C.; Holmes, E.; Harbeck, N.; Sotiriou, C.; Peña, L.; Loi, S.; Rosa, D. D.; Chia, S.; Wardley, A.; Ueno, T.; Rossari, J.; Eidtmann, H.; Armour, A.; Piccart-Gebhart, M.; Rimm, D. L.; Baselga, J. und Pusztai, L.
(2017):
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
In: Annals of Oncology, Bd. 28, Nr. 1: S. 128-135
Baselga, J.; Cortés, J.; De Laurentiis, M.; Diéras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y.-H.; Jacot, W.; Krop, I. E. und Verma, S.
(2016):
SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors.
In: Cancer Research, Bd. 76
Prat, A.; Ortega, V.; Paré, L.; Galván, P.; Oliveira, M.; Nuciforo, P.; Lluch, A.; Morales, S.; Amillano, K.; Lopez, R.; González, R.; Manso, L.; Martínez, J.; Llombart, A.; Peña, L. de la; di Cosimo, S.; Rubio, I. T.; Harbeck, N.; Baselga, J. und Cortés, J.
(2016):
Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study.
In: Cancer Research, Bd. 76
Pusztai, L.; Shi, W.; Jiang, T.; Nuciforo, P.; Holmes, E.; Harbeck, N.; Sotiriou, C.; Rimm, D.; Hatzis, C.; Pena, L. de la; Armour, A.; Piccart-Gebhart, M. und Baselga, J.
(2016):
Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies.
In: Cancer Research, Bd. 76
Baselga, J.; Cortes Castan, J.; De Laurentiis, M.; Dieras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y.-H.; Jacot, W.; Krop, I. E. und Verma, S.
(2016):
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours.
In: Annals of Oncology, Bd. 27
Wuerstlein, R.; Prat, A.; Ortega, V; Pare, L.; Galvan, P.; Nuciforo, P.; Oliverira, M.; Amillano, K.; Lopez, R.; Lluch, A.; Morales, S.; Gonzales, R.; Manso, L.; Martinez, J.; Llombart, A.; Pena, L. de la; Di Cosimo, S.; Rubio, I; Baselga, J.; Cortes, J. und Harbeck, N.
(2016):
Efficacy and gene expression results from SOLTI1007, a phase II study evaluating neoadjuvant eribulin in hormone receptor (HR)-positive/HER2-negative breast cancer.
In: Oncology Research and Treatment, Bd. 39: S. 182-183